Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ipsen S.A. ADR (OP: IPSEY )

28.83 +0.79 (+2.82%)
Streaming Delayed Price Updated: 10:26 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Ipsen S.A. ADR

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts
Virtual Investor Conference on November 8th and 9th, 2023 
From Virtual Investor Conferences
Via GlobeNewswire
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
From Virtual Investor Conferences
Via GlobeNewswire
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
From Ipsen
Via Business Wire
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
From Ipsen
Via Business Wire
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
From Ipsen
Via Business Wire
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
From Ipsen
Via Business Wire
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
From Ipsen
Via Business Wire
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
From Ipsen
Via Business Wire
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
From Ipsen
Via Business Wire
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
From Ipsen
Via Business Wire
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
From Ipsen
Via Business Wire
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
From Ipsen
Via Business Wire
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
From Ipsen
Via Business Wire
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
From Ipsen
Via Business Wire
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
From Ipsen
Via Business Wire
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
From Ipsen
Via Business Wire
Ipsen to acquire Epizyme, expanding its portfolio in oncology
From Epizyme, Inc.
Via Business Wire
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
From Ipsen
Via Business Wire
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
From Ipsen
Via Business Wire
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
From Ipsen
Via Business Wire
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
From Ipsen
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.